返回 Agenda
Session 3: Development of COVID-19 Therapeutics and Diagnostics During a Global Pandemic
Session Chair(s)
Nita Ichhpurani, PMP
Consultant To Daiichi Sankyo, Inc.
Phase One Forward, Consultant, Canada
Elizabeth Somers, MS
Executive Director, Global Project and Alliance Management
Merck Sharp & Dohme LLC, United States
In this session, we will share case studies of COVID-19 therapeutic and diagnostic development in response to the global pandemic. Through these case studies we will be able to evaluate the utilization of project management skillsets. We will explore the need to focus teams and product development strategy to enable execution amidst an evolving landscape.
Learning Objective : Upon completion of this session, the participant should be able to:
- Compare and contrast the development of therapeutics before and during a global pandemic
- Compare and contrast the development of diagnostics before and during a global pandemic
- Explain how project teams worked under intense scrutiny and with a high degree of stress and time pressure to successfully deliver products
Speaker(s)
Speaker
Kristi Huntington, MS
Eli Lilly and Company, United States
Sr. Advisor, Pharmaceutical Project Management
Speaker
John Nuckols, PhD, MS
U.S. Department of Defense, Joint Program Executive Office For Chemical, Biologi, United States
Defense Assiste Acquistioin Product Lead - Screening and Diagnostics
Speaker
Erik Mogalian, PharmD, PhD
Vir Biotechnology, Inc., United States
Vice President, Program Executive, COVID